Wednesday, April 24, 2024
4/24/2024
Abstract Q fever is a worldwide zoonotic disease that is caused by the obligate intracellular Gram-negative bacterium, Coxiella burnetii. Human Q fever can develop into a severe chronic, potentially fatal disease. Although this organism previously weaponized and currently classified as a category B select agent, no vaccine is commercially available for the prevention of human Q fever in the US. Thus, the creation of a safe and effective vaccine for preventing Q fever remains an important goal for public health and national biosecurity. To achieve this goal, this revised R21 application aims to explore the feasibility of designing a multivalent mimetic peptide Q fever vaccine targeting novel neutralization-sensitive epitopes of C. burnetii T cell-independent antigens. Despite C. burnetii being an obligate intracellular bacterial pathogen, our recent work demonstrated that formalin-inactivated Nine Mile phase I whole cell vaccine (PIV)-induced protection is B-cell dependent, requiring IgM and IgG, and that PIV-specific T cell-independent IgM plays a critical role. Thus, antigens that activate B cells to produce PIV-specific IgM are expected to be promising vaccine candidates. Interestingly, our previous studies demonstrated that a peptide mimic of a C. burnetii phase I lipopolysaccharides protective epitope (m1E41920) conjugated to keyhole limpet haemocyanin (m1E41920-KLH) conferred significant protection against C. burnetii infection. This finding supports the utility of m1E41920 as a vaccine candidate to prevent human Q fever. However, m1E41920-KLH did not confer the same level of protection as the PIV. Thus, the overall objective of this application is to define a multivalent mimotope Q fever vaccine that confers the equal level of protection as the PIV. To achieve this objective, we propose one specific aim to test the central hypothesis that a humoral response to multiple neutralization-sensitive epitopes of C. burnetii T cell- independent antigens can confer the same level of protection as the PIV. We will identify additional protective mimetic peptides of T cell-independent antigens to enhance the protection conferred by this monovalent m1E41920-based vaccine. Upon the completion of this project, we expect to define the first multivalent mimotope Q fever vaccine that targets novel neutralization-sensitive epitopes of T cell-independent antigens.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
